Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current ...

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids. They ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid ...

Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B ...

China has made significant progress in reducing mother-to-child transmission of hepatitis B, but further efforts are needed ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals.